Osteopenia Completed Phase 3 Trials for Denosumab (DB06643)

Also known as: Osteopaenia / Bone loss

DBCOND0015922 (Osteopenia)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00523341Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of OsteoporosisTreatment
NCT00089661AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast CancerTreatment
NCT00980174Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With OsteoporosisTreatment
NCT00925600A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation TherapySupportive Care
NCT00330460A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.Treatment
NCT00515463A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral DensityTreatment